Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2026–2027
7 affiliations
- 1Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, ON
- 2School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON
- 3NACI Influenza Working Group Chair
- 4Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton, AB
- 5Division of Pediatric Infectious Diseases, Department of Pediatrics, Montréal Children’s Hospital, McGill University Health Centre, Montréal, QC
- 6Division of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montréal, McGill University Health Centre, Montréal, QC
- 7Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montréal, QC
Abstract
Background: The National Advisory Committee on Immunization (NACI) reviews evolving evidence on influenza immunization annually and updates vaccine recommendations. The NACI Statement on seasonal influenza vaccines for 2026–2027 updates recommendations from the 2025–2026 season.
Objective: To highlight new and updated information since the 2025–2026 statement and to summarize the 2026–2027 NACI seasonal influenza vaccine recommendations.
Methods: The NACI Influenza Working Group applied the NACI evidence-based process to assess available evidence and formulate recommendations, which were evaluated and approved by NACI. Throughout the process, NACI’s peer-reviewed Ethics, Equity, Feasibility, and Acceptability (EEFA) framework, along with its evidence-informed tools (Ethics Integrated Filters, Equity Matrix, Feasibility Matrix, and Acceptability Matrix) were applied.
Results: The overarching recommendation for seasonal influenza vaccination remains unchanged. Key updates for the 2025–2026 statement include: 1) integration of a new evidence review on optimal timing of seasonal influenza vaccination, including consideration of intraseasonal waning, and 2) integration of guidance on seasonal influenza vaccination in the context of avian influenza, with supporting resources.
Conclusion: This guidance reaffirms NACI’s recommendation that influenza vaccine should be offered annually to anyone six months of age or older who does not have a contraindication to the vaccine.
Related
- National Immunization Technical Advisory Groups maturity and RSV vaccination policies in Europe
- Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program
- Artificial intelligence in cardiology for non-experts: decoding key terms and understanding machine learning methodologies. A Scientific Statement of the ESC Working Group on e-Cardiology, the European Heart Rhythm Association (EHRA), the Association for Acute CardioVascular Care (ACVC), the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI), the European Association of Preventive Cardiology (EAPC), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Regulatory Affairs Committee, and the ESC Digital Cardiology and Artificial Intelligence Committee
- Immunization and the hepatitis B virus: A view from the ESPGHAN Hepatology Committee
- Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global Committee
BibTeX
@article{sinilaite2026summary,
title = {{Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2026–2027}},
author = {Angela Sinilaite and Winnie Siu and Kristin Klein and Jesse Papenburg},
journal = {Canada Communicable Disease Report},
year = {2026},
month = sep,
doi = {10.14745/ccdr.v52i09a01},
url = {https://doi.org/10.14745/ccdr.v52i09a01},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2026–2027
AU - Angela Sinilaite
AU - Winnie Siu
AU - Kristin Klein
AU - Jesse Papenburg
PY - 2026
DA - 2026/09/03
JO - Canada Communicable Disease Report
DO - 10.14745/ccdr.v52i09a01
UR - https://doi.org/10.14745/ccdr.v52i09a01
AB - Background: The National Advisory Committee on Immunization (NACI) reviews evolving evidence on influenza immunization annually and updates vaccine recommendations. The NACI Statement on seasonal influenza vaccines for 2026–2027 updates recommendations from the 2025–2026 season. Objective: To highlight new and updated information since the 2025–2026 statement and to summarize the 2026–2027 NACI seasonal influenza vaccine recommendations. Methods: The NACI Influenza Working Group applied the NACI evidence-based process to assess available evidence and formulate recommendations, which were evaluated and approved by NACI. Throughout the process, NACI’s peer-reviewed Ethics, Equity, Feasibility, and Acceptability (EEFA) framework, along with its evidence-informed tools (Ethics Integrated Filters, Equity Matrix, Feasibility Matrix, and Acceptability Matrix) were applied. Results: The overarching recommendation for seasonal influenza vaccination remains unchanged. Key updates for the 2025–2026 statement include: 1) integration of a new evidence review on optimal timing of seasonal influenza vaccination, including consideration of intraseasonal waning, and 2) integration of guidance on seasonal influenza vaccination in the context of avian influenza, with supporting resources. Conclusion: This guidance reaffirms NACI’s recommendation that influenza vaccine should be offered annually to anyone six months of age or older who does not have a contraindication to the vaccine.
SN - 1188-4169
SN - 1481-8531
ER -